Berna ARLI, Ersin Kasım ULUSOY, Şule BİLEN, Gönül ERDEN, Zeynep GİNİŞ, Gülfer ÖZTÜRK, Cevdet ZÜNGÜN

Serum S100B levels in patients with obstructive sleep apnea syndrome

Amaç: Tekrarlayan faringeal daralmalar ve nefes almada zorlukla karakterize olan obstrüktif uyku apne sendromu (OSAS) santral sinir sistemini etkileyebilir. Nörotrofik ve gliotrofik özellikler gösteren S100B kalsiyum bağlayıcı bir proteindir. Bu çalışmanın amacı, OSAS bulunan hastalarda serum S100Bnin düzeylerini araştırmaktır. Gereç ve yöntem: Klinik ve laboratuvar değerlendirmeler için OSASlı 26 hasta (5 kadın ve 21 erkek) çalışmaya dahil edildi. Yaş, cinsiyet ve vücut kitle indeksi uygun 28 (8 kadın ve 20 erkek) sağlıklı gönüllü kontrol grubu olarak alındı. Hastalara uyku laboratuvarında tüm gece polisomnografi uygulandı. Serum S100B ölçümü ticari bir ELISA kiti kullanılarak yapıldı. Bulgular: Hasta ve sağlıklılar demografik özellikleri bakımından birbirleriyle uyumluydu. Serum S100B konsantrasyonları hastalar ve sağlıklı bireyler için sırasıyla, 149.4±84.5 ng/L ve 139.2±70.7 ng/L olarak bulundu. Obstrüktif uyku apne sendromu ve kontrol grubu arasında S100 B konsantrasyonlar bakımından anlamlı farklılık yoktu (p>0.05). Sonuç: Serum S100B protein düzeyinde OSASlı hastalar kontrol grubu ile karşılaştırıldığında anlamlı fark bulunmadı. Daha sonraki çalışmalarla, OSASlı hastalarda özellikle küçük serebral hasarı gösteren biyokimyasal belirteçler alanında yapılacak ileri araştırmalara ihtiyaç vardır.

Tıkayıcı uyku apne sendromlu hastalarda serum S100B düzeyleri

Objectives: Obstructive sleep apnea syndrome (OSAS) which is characterized by recurrent pharyngeal narrowing and breathing disturbances, can affect central neural system (CNS). S100B, which exerts neurotrophic and gliotrophic features, is a calcium binding protein. The aim of this study was to evaluate serum levels of S100B in patients with OSAS. Materials and methods: Clinical and laboratory assessment were performed in 26 patients (5 women and 21 men) with OSAS and 28 (8 women and 20 men) age-, body mass index (BMI)- and sex- matched healthy subjects served as controls . The patients included in the study had whole-night polysomnography (PSG) performed in the sleep laboratory. Measurements of S100B were done using the commercially available ELISA kit. Results: Patients and controls were well matched with regard to demographic characteristics. Serum S100B concentrations were 149.4±84.5 ng/L and 139.2±70.7 ng/L for patients with OSAS and control subject, respectively. There was no statistically significant difference in serum S100B concentrations between OSAS and control groups (p>0.05). Conclusions: Serum S100B protein level in serum did not significantly higher in patients with OSAS compared to the healthy subjects. However, further investigations are required, particularly in the area of biochemical markers of mild cerebral damage in patients with OSAS.

PDF

___

1. Yun CH, Jung KH, Chu K, et al. Increased circulating endothelial microparticles and carotid atherosclerosis in obstructive sleep apnea. J Clin Neurol 2010;6(2):89- 98.
2. Flemons WW. Clinical practice. Obstructive sleep apnea. N Engl J Med 2002;347(7):498-504.
3. Aviles-Reyes RX, Angelo MF, Villarreal A, et al. Intermittent hypoxia during sleep induces reactive gliosis and limited neuronal death in rats: implications for sleep apnea. J Neurochem 2010;112(4):854-69.
4. Isono S. Obesity and obstructive sleep apnoea: mechanisms for increased collapsibility of the passive pharyngeal airway. Respirology 2012;17(1):32-42.
5. da Silva LG, Mottin CC, Souza DO, Portela LV, et al. Serum S100B but not NSE levels are increased in morbidly obese individuals affected by obstructive sleep apnea-hypopnea syndrome. Obes Surg 2008;18(8):993-9.
6. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010;7(12):677-85.
7. Ziegler MG, Milic M, Elayan H. Cardiovascular Regulation in Obstructive Sleep Apnea. Drug Discov Today Dis Models 2011;8(4):155-60.
8. Uzkeser H, Yildirim K, Aktan B, et al. Bone mineral density in patients with obstructive sleep apnea syndrome. Sleep Breath April 2012 (Epub-In press).
9. Campos-Rodriguez F, Fernandez-Palacin A, Reyes- Nunez N, Reina-Gonzalez A. [Clinical and polysomnographic features of rapid-eye-movement-specific sleep-disordered breathing]. Arch Bronconeumol 2009;45(7):330-4.
10. Calvin AD, Albuquerque FN, Lopez-Jimenez F, Somers VK. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab Syndr Relat Disor 2009;7(4):271-8.
11. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60(6):540-51.
12. Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R. S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J Cell Physiol 2004;199(2):274-83.
13. Ferini-Strambi L, Fantini ML. Cerebrovascular diseases and sleep-disordered breathing. Clin Exp Hypertens 2006;28(3-4):225-31.
14. Bellander BM, Olafsson IH, Ghatan PH, et al. Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir (Wien) 2011;153(1):90-100.
15. Sharma SK, Sinha S, Danishad KA, et al. Proton magnetic resonance spectroscopy of brain in obstructive sleep apnoea in north Indian Asian subjects. Indian J Med Res 2010;132:278-86.
16. Akyol O, Herken H, Uz E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(5):995-1005.
17. Ozturk E, Demirbilek S, Kadir But A, Saricicek V, Gulec M, Akyol O, et al. Antioxidant properties of propofol and erythropoietin after closed head injury in rats. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):922-7.
18. Fadillioglu E, Gursul C, Iraz M. Effects of caffeic acid phenethyl ester on thioacetamide-induced hepatic encephalopathy in rats. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(8):1440-5.
19. Davey GE, Murmann P, Heizmann CW. Intracellular Ca2+ and Zn2+ levels regulate the alternative cell density-dependent secretion of S100B in human glioblastoma cells. J Biol Chem 2001;276(33):30819-26.
20. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004;342(1-2):1-12.
21. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000;275(51):40096- 105.
22. Gerlach R, Demel G, Konig HG, Gross U, Prehn JH, Raabe A, et al. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience 2006;141(4):1697-701.
23. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353(19):2034-41.
24. Brouns R, De Vil B, Cras P, De Surgeloose D, Marien P, De Deyn PP. Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem 2010;56(3):451-8.
25. Feng H FX, Jiang H. The changes of memory and their correlations to S100beta protein as well as neuron- specific enolase in patients with obstructive sleep apnea-hypopnea syndrome. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;25(3):105-8.
26. Braga CW, Martinez D, Wofchuk S, Portela LV, Souza DO. S100B and NSE serum levels in obstructive sleep apnea syndrome. Sleep Med 2006;7(5):431-5.
27. Jordan W, Hagedohm J, Wiltfang J, et al. Biochemical markers of cerebrovascular injury in sleep apnoea syndrome. Eur Respir J 2002;20(1):158-64.
28. Ong KC, Clerk AA. Comparison of the severity of sleep-disordered breathing in Asian and Caucasian patients seen at a sleep disorders center. Respir Med 1998;92(6):843-8.
29. Sonka K, Kelemen J, Kemlink D, et al. Evening and morning plasma levels of protein S100B in patients with obstructive sleep apnea. Neuro Endocrinol Lett 2007;28(5):575-9.
30. Portela LV, Tort AB, Schaf DV, et al. The serum S100B concentration is age dependent. Clin Chem 2002;48(6 Pt 1):950-2.